Protalix BioTherapeutics Shares Second Quarter 2025 Insights
Protalix BioTherapeutics' Financial Update for Second Quarter 2025
Company to host conference call and webcast today at 8:30 a.m. EDT
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company dedicated to developing and commercializing recombinant therapeutic proteins, recently announced financial results for the second quarter of 2025, sharing updates on its business and clinical progress.
Dror Bashan, the President and CEO of Protalix, shared insights on the company's growth trajectory, highlighting a remarkable 50% increase in revenues from product sales compared to the first half of 2024. He attributed this growth primarily to the sales of Elfabrio, a treatment for Fabry disease, to Chiesi, their commercial partner. The Fabry disease market is predicted to expand significantly, forecasted to reach approximately $3.2 billion by 2030. Dr. Bashan expressed confidence in the long-term growth of the Elfabrio franchise, especially as market patterns stabilize and demand increases.
The company is also advancing its pipeline, focusing on PRX-115, a recombinant PEGylated uricase product which aims to provide a treatment option for uncontrolled gout. Protalix anticipates beginning a randomized Phase 2 trial in the latter half of 2025, with plans to enroll the first patients by the fourth quarter. The efficacy of PRX-115 plays a key role in Protalix's strategic plans.
In recent leadership changes, Eyal Rubin will step down as Chief Financial Officer after six years of service, with Gilad Mamlok appointed to succeed him. Mamlok brings extensive experience in finance within the healthcare sector, having been involved in capital markets and business development, which will be advantageous as Protalix aims for further growth. Dr. Bashan praised Rubin’s contributions and expressed gratitude for his efforts in strengthening the company during critical growth stages.
Recent Business Highlights from Second Quarter 2025
Corporate Highlights
- Gilad Mamlok's appointment is effective from August 24, 2025. Mr. Rubin will assist in the transition before his departure in October 2025.
- Protalix has been added to the Russell 3000 and Russell 2000 Indexes as of June 27, 2025, enhancing its market visibility.
- The European Medicines Agency is currently evaluating Chiesi's submission for a new Elfabrio dosage, which could significantly impact its market positioning in treating Fabry disease.
Financial Highlights for the Second Quarter 2025
- Revenues from product sales totaled $15.4 million for the quarter, marking a significant $2.1 million increase, or 16%, compared to the same period in 2024. This growth was primarily driven by Chiesi's substantial orders, offset by decreased sales to other distributors.
- License and R&D services generated revenues of $0.2 million, reflecting limited expectations for additional revenue streams beyond potential regulatory milestones.
- Cost of goods sold decreased to $5.9 million due to the adjustments in sales mix and improved operational efficiencies.
- Total R&D expenses approximately doubled year-over-year to $6.0 million, mainly due to preparations for PRX-115's upcoming trials.
- Expenses related to selling, general and administrative costs were reduced to $2.6 million, reflecting the company's commitment to financial discipline.
- The net income reported for the quarter was approximately $164,000, a stark improvement from the previous year's net loss of $2.2 million for the same quarter.
Future Directions and Call Details
Protalix will host a conference call to discuss these results and the strategic direction of the company. This call is scheduled for today at 8:30 a.m. EDT. Participants can join the call through provided contact numbers.
About Protalix BioTherapeutics, Inc.
Protalix specializes in the development and commercialization of recombinant therapeutic proteins through its proprietary ProCellEx plant cell-based expression system. Recognized for being the first company to receive FDA approval for a plant cell-based therapeutic protein, Protalix's innovative approach is paving the way for next-generation treatments. The company has licensed key products like taliglucerase alfa for Gaucher disease and Elfabrio, recently approved for Fabry disease. Protalix aims to expand its pipeline further into established pharmaceutical markets.
Frequently Asked Questions
What financial improvement did Protalix show in the second quarter of 2025?
Protalix reported a 50% increase in revenues from product sales and a notable net income of approximately $164,000, compared to a loss in the previous year.
Who is the new CFO of Protalix?
Gilad Mamlok has been appointed as the new CFO, succeeding Eyal Rubin, who is leaving after six years in the role.
What is the main product contributing to revenue growth?
Elfabrio, a treatment for Fabry disease, is the primary product driving revenue growth, especially through sales to Chiesi.
What is the company's focus for clinical trials in 2025?
Protalix is focusing on initiating a randomized Phase 2 trial for PRX-115, targeting uncontrolled gout.
How does Protalix plan to maintain its financial health?
Protalix aims to pursue effective cost management strategies while expanding its product pipeline to enhance revenue streams.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.